RIGH
RightSmile, Inc.

LOS ANGELES, Mar 28, 2014 / OTC Disclosure & News Service / -- BG Medical Technologies, Inc. (OTC: RIGH) has submitted appropriate filings to upgrade its status on OTC Markets.

The current filings are expected to immediately upgrade the company to OTC Pink Limited. The company will follow this action by filing financial reports to amend the public entity to OTC Pink Current. 

Company CEO, Angel Stanz stated, "Through the steadfast actions of expert advisors and devout shareholders, we have reached a transformative milestone. By popular demand, the company is increasing transparency. We are committed to being open and fair in our communication with the public and shareholders as much as possible for our unique and growing industry. We have hired Securities Compliance Group, Ltd. to guide us in this process, and we will continue to work with them to find additional ways to improve."

The new reports contain news of the completed transformation from RightSmile, Inc. to BG Medical Technologies Inc., clearing the way for the company to actively focus on filing with FINRA for its name and symbol change. All significant share positions and all debt positions related to pre-merger RightSmile management have been neutralized and resolved. These accomplishments have resulted in a corporate domicile change, relieved share positions, and restricted share positions. This good news reveals that the company's number of authorized shares leaves no room for the issuance of new stock. 

BG Medical Technologies is a medical marijuana company that develops technology and research software for the natural health industry with a focus on patient solutions involving medical cannabis. The Company collects data through a network of proprietary software, utilized by patients, retail operators, and medical professionals. The Company's current flagship product, BudGenius.com, is a social web platform connecting cannabis patients to regionally available medicine that is paired to their needs. The Company operates an analytical chemistry laboratory designed for natural medicine study, utilized to determine potency and safety guidance for patients and medicine manufacturers. 

For more information please visit:

The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Contact:

Angel Stanz

Chief Executive Officer

pr@budgenius.com

(855) 723-3283